REGENXBIO (RGNX)
(Delayed Data from NSDQ)
$14.76 USD
+0.41 (2.86%)
Updated Jun 3, 2024 04:00 PM ET
After-Market: $14.78 +0.02 (0.14%) 4:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Brokerage Reports
REGENXBIO Inc. [RGNX]
Reports for Purchase
Showing records 1 - 20 ( 64 total )
Company: REGENXBIO Inc.
Industry: Medical - Biomedical and Genetics
Company: REGENXBIO Inc.
Industry: Medical - Biomedical and Genetics
Initial Ph1/2 DMD Data @ Higher RGX-202 Dose; Strength/Functional Data in H2:24
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: REGENXBIO Inc.
Industry: Medical - Biomedical and Genetics
Company: REGENXBIO Inc.
Industry: Medical - Biomedical and Genetics
Company: REGENXBIO Inc.
Industry: Medical - Biomedical and Genetics
Company: REGENXBIO Inc.
Industry: Medical - Biomedical and Genetics
Q4/FY23: RGX-202/DMD Update at MDA; ABBV-RGX-314 (SCS) Updates in 2024
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: REGENXBIO Inc.
Industry: Medical - Biomedical and Genetics
Company: REGENXBIO Inc.
Industry: Medical - Biomedical and Genetics
Rare Disease Pipeline wAMD Gene Therapy Competitor Updates; Reiterate NEUTRAL
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: REGENXBIO Inc.
Industry: Medical - Biomedical and Genetics
Company: REGENXBIO Inc.
Industry: Medical - Biomedical and Genetics
Ph2 ABBV-RGX-314 (SCS)/wAMD Trial Update; Eyes on Rare Disease Pipeline in 2024
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: REGENXBIO Inc.
Industry: Medical - Biomedical and Genetics
Company: REGENXBIO Inc.
Industry: Medical - Biomedical and Genetics
Company: REGENXBIO Inc.
Industry: Medical - Biomedical and Genetics
Company: REGENXBIO Inc.
Industry: Medical - Biomedical and Genetics
Company: REGENXBIO Inc.
Industry: Medical - Biomedical and Genetics
Q3 Financials Restructuring; 1yr Ph2 ALTITUDE Update for SCS-RGX-314/DR @ AAO
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: REGENXBIO Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology-The Wedbush Monthly Check-Up: November 2023
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: REGENXBIO Inc.
Industry: Medical - Biomedical and Genetics
Company: REGENXBIO Inc.
Industry: Medical - Biomedical and Genetics
RGX-202 Showing Signs of Strength At WMS; Focus is on Functional Data in 2024
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: REGENXBIO Inc.
Industry: Medical - Biomedical and Genetics
Emerging Pharmaceuticals - KOL Call Highlights: Diving into DMD
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: REGENXBIO Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology - The Week Ahead in Life Sciences
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D